Lithium response across generations.

Mood Disorders Center of Ottawa, Ottawa, ON, Canada.
Acta Psychiatrica Scandinavica (Impact Factor: 5.55). 11/2009; 120(5):378-85. DOI: 10.1111/j.1600-0447.2009.01454.x
Source: PubMed

ABSTRACT To describe and integrate observations from bipolar patients responsive to lithium stabilization and their children.
Selected findings are described from the clinical and biological investigations of adults meeting research criteria for bipolar disorder and for responsiveness to lithium stabilization; and from prospective studies of the children of lithium responders and non-responders.
Response to prophylactic lithium identifies a valid subtype of bipolar disorder, however the search for biological markers of lithium response, while promising, has so far remained inconclusive. Adult responders to lithium stabilization exhibit definable clinical features which are also observable in their affected children. In prospective studies the children of bipolar parents develop symptoms earlier than reported previously, with marked differences between the offspring of lithium responders and non-responders. The illness evolves in predictable clinical stages, first from non-specific sleep and anxiety disorders to mood symptoms and then, often starting in adolescence, major depressive and later activated episodes.
Investigating and comparing unequivocal responders and non-responders to long-term lithium treatment and their offspring is a fertile research strategy for addressing a multitude of clinical and research questions.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Development of novel treatments and diagnostic tools for psychiatric illness has been hindered by the absence of cellular models of disease. With the advent of cellular reprogramming, it may be possible to recapitulate the disease biology of psychiatric disorders using patient skin cells transdifferentiated to neurons. However, efficiently identifying and characterizing relevant neuronal phenotypes in the absence of well-defined pathophysiology remains a challenge. In this study, we collected fibroblast samples from patients with bipolar 1 disorder, characterized by their lithium response (n=12), and healthy control subjects (n=6). We identified a cellular phenotype in reprogrammed neurons using a label-free imaging assay based on a nanostructured photonic crystal biosensor and found that an optical measure of cell adhesion was associated with clinical response to lithium treatment. This cellular phenotype may represent a useful biomarker to evaluate drug response and screen for novel therapeutics.
    Translational Psychiatry 08/2014; 4(8):e428. DOI:10.1038/tp.2014.72 · 4.36 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: With the recognition that bipolar disorder (BD) develops in a series of predictable clinical stages, clinical and research focus has shifted increasingly into early intervention and prevention. The heritability of BD is estimated to be around 85 %; therefore, children of affected parents are an identifiable and important high-risk group. Lessons from early psychosis and other areas of medicine suggest that education for high-risk families regarding recognizable clinical stages and modifiable risk factors are a reasonable starting place. Specifically, reinforcing the importance of healthy nutrition, cardiovascular exercise, maintaining normal body mass index, and healthy coping strategies are important topics to cover. Early risk syndromes include sleep and anxiety disorders, which should be addressed with low-risk treatments, including sleep hygiene and individual psychotherapy. Typically, adolescence marks the age of onset of depressive disorders related to the bipolar diathesis. This is also the time when poor coping through substance abuse emerges. It is very important when assessing a depressed adolescent to understand the familial risk of psychiatric disorders. While psychotherapy is typically effective for mild non-psychotic depression, the acute treatment of moderate–severe major depression in adolescents and young adults with a confirmed family history of BD is a topic of considerable debate. The treatment decision should be taken together with the patient and family, with full discussion of the risks and potential benefits. Options include a closely monitored trial of low-dose antidepressant, discontinued immediately upon resolution of the depressive episode, or mood stabilizer that fits the patient profile, or a combination of these two, in addition to psychotherapy and reducing modifiable risk factors. When a high-risk subject manifests a diagnosable manic or hypomanic episode (typically years after the first depressive episode in late adolescence or adulthood) the question arises of whether to initiate prophylactic treatment. Potential candidates are those with a high recurrence risk and/or concern about the recurrence of a severe episode. Research has shown that most patients can be stabilized, with selected monotherapy individualized on the basis of the nature of the clinical course (episodic vs. non-episodic), quality of the spontaneous remission, and family history of psychiatric disorders and treatment response. Novel adjunctive treatments including nutraceuticals, antioxidants, and anti-inflammatory agents are being studied and may be helpful in high-risk individuals during the early stages of illness development.
    03/2014; 1(1):37-47. DOI:10.1007/s40501-013-0006-x
  • [Show abstract] [Hide abstract]
    ABSTRACT: To examine the efficacy and safety of short-term and long-term use of antidepressants in the treatment of bipolar disorder.
    Neural Regeneration Research 11/2013; 8(31):2962-74. DOI:10.3969/j.issn.1673-5374.2013.31.009 · 0.23 Impact Factor

Full-text (2 Sources)

Available from
May 19, 2014